Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $10.5 million.

  • Altimmune's Total Current Liabilities rose 45.94% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 45.94%. This contributed to the annual value of $10.5 million for FY2024, which is 13.79% down from last year.
  • As of FY2024, Altimmune's Total Current Liabilities stood at $10.5 million, which was down 13.79% from $12.1 million recorded in FY2023.
  • In the past 5 years, Altimmune's Total Current Liabilities registered a high of $18.3 million during FY2021, and its lowest value of $10.5 million during FY2024.
  • For the 3-year period, Altimmune's Total Current Liabilities averaged around $13.2 million, with its median value being $12.1 million (2023).
  • In the last 5 years, Altimmune's Total Current Liabilities soared by 206.41% in 2020 and then dropped by 28.80% in 2023.
  • Yearly analysis of 5 years shows Altimmune's Total Current Liabilities stood at $12.0 million in 2020, then spiked by 52.04% to $18.3 million in 2021, then declined by 6.69% to $17.1 million in 2022, then fell by 28.80% to $12.1 million in 2023, then dropped by 13.79% to $10.5 million in 2024.